Epithelial-mesenchymal transition in ovarian carcinoma

Frontiers in Oncology

Volumn 2, Issue APR, 2012, Pages

  Davidson, Ben ^a,b   Tropé, Claes G ^a,b   Reich, Reuven ^c,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Chemotherapy; Epithelial mesenchymal transition; Mesenchymal epithelial transition; Metastasis; Ovarian carcinoma; Prognosis; Tumor progression

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; CLAUDIN; CLAUDIN 4; CYCLOOXYGENASE 2; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR; ESTRADIOL; FIBROBLAST GROWTH FACTOR; MATRIX METALLOPROTEINASE; MICRORNA; PARATHYROID HORMONE; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN E2; SCATTER FACTOR; SEMAPHORIN; SEMAPHORIN 3E; SOMATOMEDIN; STEM CELL FACTOR; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; ZEB PROTEIN; ZINC FINGER TRANSCRIPTION FACTOR;

ANGIOGENESIS; CELL ADHESION; CELL INVASION; CELL POLARITY; EMBRYO DEVELOPMENT; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; MESENCHYME CELL; METASTASIS; NONHUMAN; OVARY CARCINOMA; OVERALL SURVIVAL; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SNAIL; TRANSCRIPTION REGULATION; TUMOR GROWTH;

EID: 84870233792     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2012.00033     Document Type: Review

References (138)

1. Acloque, H., Adams, M. S., Fishwick, K., Bronner-Fraser, M., and Nieto, M. A. (2009). Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J. Clin. Invest. 119, 1438-1449.
2. Agarwal, R., and Kaye, S. B. (2003). Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 3, 502-516.
3. Ahmed, N., Thompson, E. W., and Quinn, M. A. (2007). Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J. Cell. Physiol. 213, 581-588.
4. Akahira, J. I., Yoshikawa, H., Shimizu, Y., Tsunematsu, R., Hirakawa, T., Kuramoto, H., Shiromizu, K., Kuzuya, K., Kamura, T., Kikuchi, Y., Kodama, S., Yamamoto, K., and Sato, S. (2001). Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol. Oncol. 81, 398-403.
5. Bani, M. R., Nicoletti, M. I., Alkharouf, N. W., Ghilardi, C., Petersen, D., Erba, E., Sausville, E. A., Liu, E. T., and Giavazzi, R. (2004). Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol. Cancer Ther. 3, 111-121.
6. Bendoraite, A., Knouf, E. C., Garg, K. S., Parkin, R. K., Kroh, E. M., O'Briant, K. C., Ventura, A. P., Godwin, A. K., Karlan, B. Y., Drescher, C. W., Urban, N., Knudsen, B. S., and Tewari, M. (2010). Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol. Oncol. 116, 117-125.
7. Bignotti, E., Tassi, R. A., Calza, S., Ravaggi, A., Romani, C., Rossi, E., Falchetti, M., Odicino, F. E., Pecorelli, S., and Santin, A. D. (2006). Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol. Oncol. 103, 405-416.
8. Blechschmidt, K., Sassen, S., Schmalfeldt, B., Schuster, T., Höfler, H., and Becker, K. F. (2008). The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br. J. Cancer 98, 489-495.
9. Bonnefoi, H., A'Hern, R. P., Fisher, C., Macfarlane, V., Barton, D., Blake, P., Shepherd, J. H., and Gore, M. E. (1999). Natural history of stage IV epithelial ovarian cancer. J. Clin. Oncol. 17, 765-775.
10. Boylan, K. L., Misemer, B., Derycke, M. S., Andersen, J. D., Harrington, K. M., Kalloger, S. E., Gilks, C. B., Pambuccian, S. E., and Skubitz, A. P. (2011). Claudin 4 is differentially expressed between ovarian cancer subtypes and plays a role in spheroid formation. Int. J. Mol. Sci. 12, 334-358.
11. Brabletz, S., and Brabletz, T. (2010). The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer? EMBO Rep. 11, 670-677.
12. Browne, G., Sayan, A. E., and Tulchinsky, E. (2010). ZEB proteins link cell motility with cell cycle control and cell survival in cancer. Cell Cycle 9, 886-891.
13. Cannistra, S. A. (2004). Cancer of the ovary. N. Engl. J. Med. 351, 2519-2529.
14. Cao, L., Shao, M., Schilder, J., Guise, T., Mohammad, K. S., and Matei, D. (2012). Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene. doi:10.1038/onc.2011.429. [Epub ahead of print].
15. Casagrande, F., Cocco, E., Bellone, S., Richter, C. E., Bellone, M., Todeschini, P., Siegel, E., Varughese, J., Arin-Silasi, D., Azodi, M., Rutherford, T. J., Pecorelli, S., Schwartz, P. E., and Santin, A. D. (2011). Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer 117, 5519-5528.
16. Cavallaro, U., and Christofori, G. (2004). Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer 4, 118-132.
17. Chao, A., Lin, C. Y., Lee, Y. S., Tsai, C. L., Wei, P. C., Hsueh, S., Wu, T. I., Tsai, C. N., Wang, C. J., Chao, A. S., Wang, T. H., and Lai, C. H. (2012). Regulation of ovarian cancer progression by microRNA-187 through targeting disabled homolog-2. Oncogene 31, 764-775.
18. Chen, J., Wang, L., Matyunina, L. V., Hill, C. G., and McDonald, J. F. (2011). Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol. Oncol. 121, 200-205.
19. Cheng, J. C., Klausen, C., and Leung, P. C. (2010). Hydrogen peroxide mediates EGF-induced down-regulation of E-cadherin expression via p38 MAPK and snail in human ovarian cancer cells. Mol. Endocrinol. 24, 1569-1580.
20. Choi, Y. L., Kim, J., Kwon, M. J., Choi, J. S., Kim, T. J., Bae, D. S., Koh, S. S., In, Y. H., Park, Y. W., Kim, S. H., Ahn, G., and Shin, Y. K. (2007). Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation. Histol. Histopathol. 22, 1185-1195.
21. Cocco, E., Casagrande, F., Bellone, S., Richter, C. E., Bellone, M., Todeschini, P., Holmberg, J. C., Fu, H. H., Montagna, M. K., Mor, G., Schwartz, P. E., Arin-Silasi, D., Azoudi, M., Rutherford, T. J., Abu-Khalaf, M., Pecorelli, S., and Santin, A. D. (2010). Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer. BMC Cancer 10, 349. doi:10.1186/1471-2407-10-349
22. Comamala, M., Pinard, M., Thériault, C., Matte, I., Albert, A., Boivin, M., Beaudin, J., Piché, A., and Rancourt, C. (2011). Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Br. J. Cancer 104, 989-999.
23. Cormio, G., Maneo, A., Parma, G., Pittelli, M. R., Miceli, M. D., and Bonazzi, C. (1995). Central nervous system metastases in patients with ovarian carcinoma. A report of 23 cases and literature review. Ann. Oncol. 6, 571-574.
24. Cowden Dahl, K. D., Dahl, R., Kruichak, J. N., and Hudson, L. G. (2009). The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia 11, 1208-1215.
25. Curtin, J. P., Malik, R., Venkatraman, E. S., Barakat, R. R., and Hoskins, W. J. (1997). Stage IV ovarian cancer: impact of surgical debulking. Gynecol. Oncol. 64, 9-12.
26. Dahiya, N., Becker, K. G., Wood, W. H. III, Zhang, Y., and Morin, P. J. (2011). Claudin-7 is frequently overexpressed in ovarian cancer and promotes invasion. PLoS ONE 6, e22119. doi:10.1371/journal.pone.0022119
27. Dannenmann, C., Shabani, N., Friese, K., Jeschke, U., Mylonas, I., and Brüning, A. (2008). The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO. Cancer Biol. Ther. 7, 1460-1467.
28. Darai, E., Scoazec, J. Y., Walker-Combrouze, F., Mlika-Cabanne, N., Feldmann, G., Madelenat, P., and Potet, F. (1997). Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum. Pathol. 28, 922-928.
29. Davidson, B., Baekelandt, M., and Shih, I. M. (2007). MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Diagn. Cytopathol. 35, 756-760.
30. Davidson, B., Berner, A., Nesland, J. M., Risberg, B., Berner, H. S., Tropé, C. G., Kristensen, G. B., Bryne, M., and Flørenes, V. A. (2000a). E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. J. Pathol. 192, 460-469.
31. Davidson, B., Gotlieb, W. H., Ben-Baruch, G., Nesland, J. M., Bryne, M., Goldberg, I., Kopolovic, J., and Berner, A. (2000b). E-cadherin complex protein expression and survival in ovarian carcinoma. Gynecol. Oncol. 79, 362-371.
32. Davidson, B., Goldberg, I., Gotlieb, W. H., Kopolovic, J., Ben-Baruch, G., and Reich, R. (2003). PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. Clin. Cancer Res. 9, 1412-1419.
33. Davidson, B., Goldberg, I., Reich, R., Tell, L., Baekelandt, M., Kristensen, G. B., Berner, A., and Kopolovic, J. (2004). The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions. Clin. Exp. Metastasis 21, 191-199.
34. Davidson, B., Zhang, Z., Kleinberg, L., Li, M., Flørenes, V. A., Wang, T. L., and Shih, I. M. (2006). Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin. Cancer Res. 12, 5944-5950.
35. Ding, J. X., Feng, Y. J., Yao, L. Q., Yu, M., Jin, H. Y., and Yin, L. H. (2006). The reinforcement of invasion in epithelial ovarian cancer cells by 17 beta-estradiol is associated with up-regulation of Snail. Gynecol. Oncol. 103, 623-630.
36. Elloul, S., Elstrand, M. B., Nesland, J. M., Tropé, C. G., Kvalheim, G., Goldberg, I., Reich, R., and Davidson, B. (2005). Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 103, 1631-1643.
37. Elloul, S., Silins, I., Tropé, C. G., Benshushan, A., Davidson, B., and Reich, R. (2006). Expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Arch. 449, 520-528.
38. Elloul, S., Vaksman, O., Stavnes, H. T., Tropé, C. G., Davidson, B., and Reich, R. (2010). Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions. Clin. Exp. Metastasis 27, 161-172.
39. Faleiro-Rodrigues, C., Macedo-Pinto, I., Pereira, D., and Lopes, C. S. (2004). Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann. Oncol. 15, 1535-1542.
40. Fedele, M., and Fusco, A. (2010). HMGA and cancer. Biochim. Biophys. Acta 1799, 48-54.
41. Feldman, G. B., Knapp, R. C., Order, S. E., and Hellman, S. (1972). The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res. 32, 1663-1666.
42. Filipowicz, W., Bhattacharyya, S. N., and Sonenberg, N. (2008). Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 9, 102-114.
43. Franco, H. L., Casasnovas, J., Rodríguez-Medina, J. R., and Cadilla, C. L. (2011). Redundant or separate entities?-roles of Twist1 and Twist2 as molecular switches during gene transcription. Nucleic Acids Res. 39, 1177-1186. doi:10.1186/1471-2407-6-186
44. Gao, Z., Xu, X., McClane, B., Zeng, Q., Litkouhi, B., Welch, W. R., Berkowitz, R. S., Mok, S. C., and Garner, E. I. (2011). C terminus of Clostridium perfringens enterotoxin downregulates CLDN4 and sensitizes ovarian cancer cells to Taxol and Carboplatin. Clin. Cancer Res. 17, 1065-1074.
45. González-Mariscal, L., Betanzos, A., Nava, P., and Jaramillo, B. E. (2003). Tight junction proteins. Prog. Biophys. Mol. Biol. 81, 1-44.
46. Heinzelmann-Schwarz, V. A., Gardiner-Garden, M., Henshall, S. M., Scurry, J., Scolyer, R. A., Davies, M. J., Heinzelmann, M., Kalish, L. H., Bali, A., Kench, J. G., Edwards, L. S., Vanden Bergh, P. M., Hacker, N. F., Sutherland, R. L., and O'Brien, P. M. (2004). Overexpression of the cell adhesion molecules DDR1, claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin. Cancer Res. 10, 4427-4436.
47. Helleman, J., Smid, M., Jansen, M. P., van der Burg, M. E., and Berns, E. M. (2010). Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture. Gynecol. Oncol. 117, 170-176.
48. Hemavathy, K., Ashraf, S. I., and Ip, Y. T. (2000). Snail/Slug family of repressors: slowly going into the fast lane of development and cancer. Gene 257, 1-12.
49. Hennessy, B. T., Coleman, R. L., and Markman, M. (2009). Ovarian cancer. Lancet 374, 1371-1382.
50. Hewitt, K. J., Agarwal, R., and Morin, P. J. (2006). The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 6, 186.
51. Hibbs, K., Skubitz, K. M., Pambuccian, S. E., Casey, R. C., Burleson, K. M., Oegema, T. R. Jr., Thiele, J. J., Grindle, S. M., Bliss, R. L., and Skubitz, A. P. (2004). Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am. J. Pathol. 165, 397-414.
52. Hipp, S., Berg, D., Ergin, B., Schuster, T., Hapfelmeier, A., Walch, A., Avril, S., Schmalfeldt, B., Höfler, H., and Becker, K. F. (2010). Interaction of Snail and p38 mitogen-activated protein kinase results in shorter overall survival of ovarian cancer patients. Virchows Arch. 457, 705-713.
53. Hirabayashi, K., and Graham, J. (1970). The genesis of ascites in ovarian cancer. Am. J. Obstet. Gynecol. 106, 492-497.
54. Hosono, S., Kajiyama, H., Terauchi, M., Shibata, K., Ino, K., Nawa, A., and Kikkawa, F. (2007). Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients. Br. J. Cancer 96, 314-320.
55. Hough, C. D., Sherman-Baust, C. A., Pizer, E. S., Montz, F. J., Im, D. D., Rosenshein, N. B., Cho, K. R., Riggins, G. J., and Morin, P. J. (2000). Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 60, 6281-6287.
56. Hudson, L. G., Zeineldin, R., and Stack, M. S. (2008). Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin. Exp. Metastasis 25, 643-655.
57. Hurt, E. M., Saykally, J. N., Anose, B. M., Kalli, K. R., and Sanders, M. M. (2008). Expression of the ZEB1 (deltaEF1) transcription factor in human: additional insights. Mol. Cell. Biochem. 318, 89-99.
58. Ibrahim, N., He, L., Leong, C. O., Xing, D., Karlan, B. Y., Swisher, E. M., Rueda, B. R., Orsulic, S., and Ellisen, L. W. (2010). BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma. Cancer Res. 70, 7155-7165.
59. Imai, T., Horiuchi, A., Wang, C., Oka, K., Ohira, S., Nikaido, T., and Konishi, I. (2003). Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am. J. Pathol. 163, 1437-1447.
60. Jin, H., Yu, Y., Zhang, T., Zhou, X., Zhou, J., Jia, L., Wu, Y., Zhou, B. P., and Feng, Y. (2010). Snail is critical for tumor growth and metastasis of ovarian carcinoma. Int. J. Cancer 126, 2102-2111.
61. Kajiyama, H., Hosono, S., Terauchi, M., Shibata, K., Ino, K., Yamamoto, E., Nomura, S., Nawa, A., and Kikkawa, F. (2006). Twist expression predicts poor clinical outcome of patients with clear cell carcinoma of the ovary. Oncology 71, 394-401.
62. Kajiyama, H., Shibata, K., Terauchi, M., Yamashita, M., Ino, K., Nawa, A., and Kikkawa, F. (2007). Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int. J. Oncol. 31, 277-283.
63. Kalluri, R., and Weinberg, R. A. (2009). The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420-1428.
64. Kim, C. J., Lee, J. W., Choi, J. J., Choi, H. Y., Park, Y. A., Jeon, H. K., Sung, C. O., Song, S. Y., Lee, Y. Y., Choi, C. H., Kim, T. J., Lee, J. H., Kim, B. G., and Bae, D. S. (2011). High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma. Eur. J. Cancer 47, 918-925.
65. Kleinberg, L., Holth, A., Fridman, E., Schwartz, I., Shih, I. M., and Davidson, B. (2007). The diagnostic role of claudins in serous effusions. Am. J. Clin. Pathol. 127, 928-937.
66. Kleinberg, L., Holth, A., Trope', C. G., Reich, R., and Davidson, B. (2008). Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Hum. Pathol. 39, 747-757.
67. Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., Prentice, L. M., Miller, D., Santos, J., Swenerton, K., Gilks, C. B., and Huntsman, D. (2008). Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 5, e232. doi:10.1371/journal.pmed.0050232
68. Kurrey, N. K., Amit, K., and Bapat, S. A. (2005). Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. Gynecol. Oncol. 97, 155-165.
69. Latifi, A., Abubaker, K., Castrechini, N., Ward, A. C., Liongue, C., Dobill, F., Kumar, J., Thompson, E. W., Quinn, M. A., Findlay, J. K., and Ahmed, N. (2011). Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J. Cell. Biochem. 112, 2850-2864.
70. Law, A. Y., and Wong, C. K. (2010). Stanniocalcin-2 promotes epithelial-mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells. Exp. Cell Res. 316, 3425-3434.
71. Le Page, C., Puiffe, M. L., Meunier, L., Zietarska, M., de Ladurantaye, M., Tonin, P. N., Provencher, D., and Mes-Masson, A. M. (2009). BMP-2 signaling in ovarian cancer and its association with poor prognosis. J. Ovarian Res. 2, 4.
72. Li, J., Sherman-Baust, C. A., Tsai-Turton, M., Bristow, R. E., Roden, R. B., and Morin, P. J. (2009a). Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer 9, 244. doi:10.1186/1471-2407-9-244
73. Li, J., Chigurupati, S., Agarwal, R., Mughal, M. R., Mattson, M. P., Becker, K. G., Wood, W. H. III, Zhang, Y., and Morin, P. J. (2009b). Possible angiogenic roles for claudin-4 in ovarian cancer. Cancer Biol. Ther. 8, 1806-1814.
74. Lim, R., Ahmed, N., Borregaard, N., Riley, C., Wafai, R., Thompson, E. W., Quinn, M. A., and Rice, G. E. (2007). Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int. J. Cancer 120, 2426-2434.
75. Llauradó, M., Abal, M., Castellví, J., Cabrera, S., Gil-Moreno, A., Pérez-Benavente, A., Colás, E., Doll, A., Dolcet, X., Matias-Guiu, X., Vazquez-Levin, M., Reventós, J., and Ruiz, A. (2012). ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells. Int. J. Cancer 130, 1532-1543.
76. Lonardi, S., Manera, C., Marucci, R., Santoro, A., Lorenzi, L., and Facchetti, F. (2011). Usefulness of Claudin 4 in the cytological diagnosis of serosal effusions. Diagn. Cytopathol. 39, 313-317.
77. López-Novoa, J. M., and Nieto, M. A. (2009). Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol. Med. 1, 303-314.
78. Lu, K. H., Patterson, A. P., Wang, L., Marquez, R. T., Atkinson, E. N., Baggerly, K. A., Ramoth, L. R., Rosen, D. G., Liu, J., Hellstrom, I., Smith, D., Hartmann, L., Fishman, D., Berchuck, A., Schmandt, R., Whitaker, R., Gershenson, D. M., Mills, G. B., and Bast, R. C. Jr. (2004). Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 10, 3291-3300.
79. Mahajan, A., Liu, Z., Gellert, L., Zou, X., Yang, G., Lee, P., Yang, X., and Wei, J. J. (2010). HMGA2: a biomarker significantly over-expressed in high grade ovarian serous carcinoma. Mod. Pathol. 23, 673-681.
80. Mamuya, F. A., and Duncan, M. K. (2012). aV integrins and TGF-β induced EMT; a circle of regulation. J. Cell Mol. Med. 16, 445-455.
81. Mezzanzanica, D., Bagnoli, M., De Cecco, L., Valeri, B., and Canevari, S. (2010). Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int. J. Biochem. Cell Biol. 42, 1262-1272.
82. Morita, K., Furuse, M., Fujimoto, K., and Tsukita, S. (1999). Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc. Natl. Acad. Sci. U.S.A. 96, 511-516.
83. Nagy, J. A., Masse, E. M., Herzberg, K. T., Meyers, M. S., Yeo, K. T., Yeo, T. K., Sioussat, T. M., and Dvorak, H. F. (1995). Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites tumor accumulation. Cancer Res. 55, 360-368.
84. Nelson, K. M., and Weiss, G. J. (2008). MicroRNAs and cancer: past, present, and potential future. Mol. Cancer Ther. 7, 3655-3660.
85. Nieto, M. A. (2002). The snail superfamily of zinc-finger transcription factors. Nat. Rev. Mol. Cell Biol. 3, 155-166.
86. Park, S. H., Cheung, L. W., Wong, A. S., and Leung, P. C. (2008a). Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. Mol. Endocrinol. 22, 2085-2098.
87. Park, S. M., Gaur, A. B., Lengyel, E., and Peter, M. E. (2008b). The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22, 894-907.
88. Patel, I. S., Madan, P., Getsios, S., Bertrand, M. A., and MacCalman, C. D. (2003). Cadherin switching in ovarian cancer progression. Int. J. Cancer 106, 172-177.
89. Pecina-Slaus, N. (2003). Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int. 3, 17.
90. Peinado, H., Olmeda, D., and Cano, A. (2007). Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 7, 415-428.
91. Pon, Y. L., Zhou, H. Y., Cheung, A. N., Ngan, H. Y., and Wong, A. S. (2008). p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells. Cancer Res. 68, 6524-6532.
92. Ponnusamy, M. P., Lakshmanan, I., Jain, M., Das, S., Chakraborty, S., Dey, P., and Batra, S. K. (2010). MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene 29, 5741-5754.
93. Prat, J. (2012). Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 460, 237-249.
94. Quattrocchi, L., Green, A. R., Martin, S., Durrant, L., and Deen, S. (2011). The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression. Virchows Arch. 459, 21-29.
95. Romani, C., Comper, F., Bandiera, E., Ravaggi, A., Bignotti, E., Tassi, R. A., Pecorelli, S., and Santin, A. D. (2009). Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. Am. J. Obstet. Gynecol. 201, 70.e1-70.e9.
96. Rosanò, L., Cianfrocca, R., Spinella, F., Di Castro, V., Nicotra, M. R., Lucidi, A., Ferrandina, G., Natali, P. G., and Bagnato, A. (2011). Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin. Cancer Res. 17, 2350-2360.
97. Rosanò, L., Spinella, F., Di Castro, V., Nicotra, M. R., Dedhar, S., de Herreros, A. G., Natali, P. G., and Bagnato, A. (2005). Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res. 65, 11649-11657.
98. Saeki, R., Kondoh, M., Kakutani, H., Tsunoda, S., Mochizuki, Y., Hamakubo, T., Tsutsumi, Y., Horiguchi, Y., and Yagi, K. (2009). A novel tumor-targeted therapy using a claudin-4-targeting molecule. Mol. Pharmacol. 76, 918-926.
99. Sakai, K., Kamura, T., Hirakawa, T., Saito, T., Kaku, T., and Nakano, H. (1997). Relationship between pelvic lymph node involvement and other disease sites in patients with ovarian cancer. Gynecol. Oncol. 65, 164-168.
100. Sandhu, S., and Garzon, R. (2011). Potential applications of microRNAs in cancer diagnosis, prognosis, and treatment. Semin. Oncol. 38, 781-787.
101. Santin, A. D., Zhan, F., Bellone, S., Palmieri, M., Cane, S., Bignotti, E., Anfossi, S., Gokden, M., Dunn, D., Roman, J. J., O'Brien, T. J., Tian, E., Cannon, M. J., Shaughnessy, J. Jr., and Pecorelli, S. (2004). Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int. J. Cancer 112, 14-25.
102. Shao, M., Cao, L., Shen, C., Satpathy, M., Chelladurai, B., Bigsby, R. M., Nakshatri, H., and Matei, D. (2009). Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res. 69, 9192-9201.
103. Siegel, R., Ward, E., Brawley, O., and Jemal, A. (2011). Cancer statistics, 2011. CA Cancer J. Clin. 61, 212-236.
104. Sivertsen, S., Berner, A., Michael, C. W., Bedrossian, C., and Davidson, B. (2006). Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions. Acta Cytol. 50, 603-607.
105. Su, H. Y., Lai, H. C., Lin, Y. W., Liu, C. Y., Chen, C. K., Chou, Y. C., Lin, S. P., Lin, W. C., Lee, H. Y., and Yu, M. H. (2010). Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int. J. Cancer 127, 555-567.
106. Sun, C., Yi, T., Song, X., Li, S., Qi, X., Chen, X., Lin, H., He, X., Li, Z., Wei, Y., and Zhao, X. (2011). Efficient inhibition of ovarian cancer by short hairpin RNA targeting claudin-3. Oncol. Rep. 26, 193-200.
107. Suzuki, M., Kato-Nakano, M., Kawamoto, S., Furuya, A., Abe, Y., Misaka, H., Kimoto, N., Nakamura, K., Ohta, S., and Ando, H. (2009). Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers. Cancer Sci. 100, 1623-1630.
108. Tassi, R. A., Bignotti, E., Falchetti, M., Ravanini, M., Calza, S., Ravaggi, A., Bandiera, E., Facchetti, F., Pecorelli, S., and Santin, A. D. (2008). Claudin-7 expression in human epithelial ovarian cancer. Int. J. Gynecol. Cancer 18, 1262-1271.
109. Terauchi, M., Kajiyama, H., Yamashita, M., Kato, M., Tsukamoto, H., Umezu, T., Hosono, S., Yamamoto, E., Shibata, K., Ino, K., Nawa, A., Nagasaka, T., and Kikkawa, F. (2007). Possible involvement of TWIST in enhanced peritoneal metastasis of epithelial ovarian carcinoma. Clin. Exp. Metastasis 24, 329-339.
110. Thériault, B. L., Shepherd, T. G., Mujoomdar, M. L., and Nachtigal, M. W. (2007). BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells. Carcinogenesis 28, 1153-1162.
111. Thiery, J. P. (2002). Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2, 442-454.
112. Thiery, J. P., Acloque, H., Huang, R. Y., and Nieto, M. A. (2009). Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890.
113. Tomassetti, A., De Santis, G., Castellano, G., Miotti, S., Mazzi, M., Tomasoni, D., Van Roy, F., Carcangiu, M. L., and Canevari, S. (2008). Variant HNF1 modulates epithelial plasticity of normal and transformed ovary cells. Neoplasia 10, 1481-1492. [3 pages following 1492].
114. Tseng, C. H., Murray, K. D., Jou, M. F., Hsu, S. M., Cheng, H. J., and Huang, P. H. (2011). Sema3E/plexin-D1 mediated epithelial-to-mesenchymal transition in ovarian endometrioid cancer. PLoS ONE 6, e19396. doi:10.1371/journal.pone.0019396
115. Tsukita, S., Furuse, M., and Itoh, M. (2001). Multifunctional strands in tight junctions. Nat. Rev. Mol. Cell Biol. 2, 285-293.
116. Tsuruchi, N., Kamura, T., Tsukamoto, N., Akazawa, K., Saito, T., Kaku, T., To, N., and Nakano, H. (1993). Relationship between paraaortic lymph node involvement and intraperitoneal spread in patients with ovarian cancer-a multivariate analysis. Gynecol. Oncol. 49, 51-55.
117. Tuhkanen, H., Soini, Y., Kosma, V. M., Anttila, M., Sironen, R., Hämäläinen, K., Kukkonen, L., Virtanen, I., and Mannermaa, A. (2009). Nuclear expression of Snail1 in borderline and malignant epithelial ovarian tumours is associated with tumour progression. BMC Cancer 9, 289. doi:10.1186/1471-2407-9-289
118. Turunen, M., Talvensaari-Mattila, A., Soini, Y., and Santala, M. (2009). Claudin-5 overexpression correlates with aggressive behavior in serous ovarian adenocarcinoma. Anticancer Res. 29, 5185-5189.
119. Vaksman, O., Tuft Stavnes, H., Kærn, J., Trope', C. G., Davidson, B., and Reich, R. (2011). miRNA profiling along tumor progression in ovarian carcinoma. J. Cell. Mol. Med. 15, 1593-1602.
120. Van Itallie, C. M., and Anderson, J. M. (2006). Claudins and epithelial paracellular transport. Annu. Rev. Physiol. 68, 403-429.
121. Vernon, A. E., and LaBonne, C. (2004). Tumor metastasis: a new twist on epithelial-mesenchymal transitions. Curr. Biol. 14, R719-R721.
122. Wang, J., Cai, J., Han, F., Yang, C., Tong, Q., Cao, T., Wu, L., and Wang, Z. (2011). Silencing of CXCR4 blocks progression of ovarian cancer and depresses canonical Wnt signaling pathway. Int. J. Gynecol. Cancer 21, 981-987.
123. Wang, X., Ling, M. T., Guan, X. Y., Tsao, S. W., Cheung, H. W., Lee, D. T., and Wong, Y. C. (2004). Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 23, 474-482.
124. Wang, Y., Sheng, Q., Spillman, M. A., Behbakht, K., and Gu, H. (2012). Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. Oncogene. doi:10.1038/onc.2011.435. [Epub ahead of print].
125. Wu, J., Liu, Z., Shao, C., Gong, Y., Hernando, E., Lee, P., Narita, M., Muller, W., Liu, J., and Wei, J. J. (2011). HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res. 71, 349-359.
126. Wu, Y., and Zhou, B. P. (2010). Snail: more than EMT. Cell Adh. Migr. 4, 199-203.
127. Xu, Z., Jiang, Y., Steed, H., Davidge, S., and Fu, Y. (2010). TGFβ and EGF synergistically induce a more invasive phenotype of epithelial ovarian cancer cells. Biochem. Biophys. Res. Commun. 401, 376-381.
128. Yagi, H., Yotsumoto, F., and Miyamoto, S. (2008). Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. Mol. Cancer Ther. 7, 3441-3451.
129. Yeasmin, S., Nakayama, K., Rahman, M. T., Rahman, M., Ishikawa, M., Katagiri, A., Iida, K., Nakayama, N., and Miyazaki, K. (2011). Loss of MKK4 expression in ovarian cancer: a potential role for the epithelial to mesenchymal transition. Int. J. Cancer 128, 94-104.
130. Yin, G., Chen, R., Alvero, A. B., Fu, H. H., Holmberg, J., Glackin, C., Rutherford, T., and Mor, G. (2010). TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 29, 3545-3553.
131. Yoshida, H., Sumi, T., Zhi, X., Yasui, T., Honda, K., and Ishiko, O. (2011). Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer. Anticancer Res. 31, 1271-1277.
132. Yoshida, J., Horiuchi, A., Kikuchi, N., Hayashi, A., Osada, R., Ohira, S., Shiozawa, T., and Konishi, I. (2009a). Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and progression. Med. Mol. Morphol. 42, 82-91.
133. Yoshida, S., Furukawa, N., Haruta, S., Tanase, Y., Kanayama, S., Noguchi, T., Sakata, M., Yamada, Y., Oi, H., and Kobayashi, H. (2009b). Expression profiles of genes involved in poor prognosis of epithelial ovarian carcinoma: a review. Int. J. Gynecol. Cancer 19, 992-997.
134. Yuan, X., Lin, X., Manorek, G., Kanatani, I., Cheung, L. H., Rosenblum, M. G., and Howell, S. B. (2009). Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. Mol. Cancer Ther. 8, 1906-1915.
135. Yue, P., Zhang, X., Paladino, D., Sengupta, B., Ahmad, S., Holloway, R. W., Ingersoll, S. B., and Turkson, J. (2012). Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. Oncogene. doi:10.1038/onc.2011.409. [Epub ahead of print].
136. Zeisberg, M., and Neilson, E. G. (2009). Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 119, 1429-1437.
137. Zhu, Y., Nilsson, M., and Sundfeldt, K. (2010). Phenotypic plasticity of the ovarian surface epithelium: TGF-beta 1 induction of epithelial to mesenchymal transition (EMT) in vitro. Endocrinology 151, 5497-5505.
138. Zhu, Y., and Sundfeldt, K. (2007). Tight junction formation in epithelial ovarian adenocarcinoma. Acta Obstet. Gynecol. Scand. 86, 1011-1019.